A prospective study of placental-derived autologous mesenchymal stem cells in the treatment of premature infants with brain injury

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037229

Enrollment

Unknown

Registered

2020-08-27

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain injury

Interventions

experimental group:Mesenchymal stem cells

Control group:Mononuclear cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent signed by the legal representative or parents; 2. Gestational age < 32 weeks, weight < 1500 g, no gender limit; 3. Meet the diagnostic criteria for brain injury in premature infants.

Exclusion criteria

Exclusion criteria: 1. Important laboratory tests (liver and kidney function tests, cardiac markers, hematology and immune tests, urinalysis, etc.) are abnormal Participants are more than three times the normal value; 2. Children who will undergo surgery within 72 hours before and after this study; 3. Children who are deemed inappropriate by the researcher.

Design outcomes

Primary

Measure	Time frame
The incidence of neurological abnormalities;Serious adverse event;	—

Secondary

Measure	Time frame
vital signs;Blood routine;Liver and kidney function;Myocardial enzyme profile;Immune Function;Tumorigenic or teratogenic event;Cranial imaging;mortality rate;Inflammatory factors;	—

Countries

China

Contacts

Public ContactLi Mengchun

Army Medical Center of PLA (Daping Hospital)

1501525017@qq.com+86 15023365250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026